Nilotinib Teva

Nilotinib, the active ingredient in Nilotinib Teva, is a tyrosine kinase inhibitor presented as an unknown/unknown for oral use. It treats chronic myeloid leukemia in the chronic phase and Philadelphia chromosome‑positive acute lymphoblastic leukemia in patients whose disease expresses the BCR‑ABL fusion protein.

GNH USA supplies Nilotinib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nilotinib acts on BCR‑ABL driven leukemias and is used in the following indications: - Chronic myeloid leukemia (chronic phase): improves hematologic, cytogenetic and molecular response rates. - Philadelphia chromosome‑positive acute lymphoblastic leukemia: contributes to remission induction when combined with chemotherapy. - Philadelphia chromosome‑positive accelerated phase CML: helps achieve disease control and prolongs survival.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: watery stools that may require hydration. - Rash: skin erythema or pruritus. - Fatigue: reduced energy levels.

Serious or Rare Side Effects: - QT interval prolongation: may predispose to cardiac arrhythmias. - Pancreatitis: abdominal pain with elevated enzymes. - Severe hepatic injury: marked elevation of transaminases. - Stevens‑Johnson syndrome: severe mucocutaneous reaction. - Cardiovascular events: myocardial ischemia or stroke. - Severe neutropenia: increased infection risk.

Before initiating therapy, clinicians should assess baseline organ function and cardiac status. - ECG monitoring: evaluate QT interval before and during treatment. - Liver function tests: check ALT/AST regularly. - Blood glucose: monitor for hyperglycemia, especially in diabetic patients. - CYP3A4 interactions: avoid strong inhibitors and adjust dose if inducers are used. - Store at room temperature: keep in the original container, protect from moisture and light.

Nilotinib has several clinically relevant drug interactions. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nilotinib exposure. - QT‑prolonging agents (e.g., amiodarone, fluoroquinolones): additive risk of arrhythmia. - Antacids containing aluminum or magnesium: reduce oral absorption. Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower drug levels. - Warfarin: may alter INR, requiring closer coagulation monitoring.